Bupranolol

Jump to: navigation, search
Bupranolol
Bupranolol.PNG
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, topical (eye drops)
ATC code
Pharmacokinetic data
Bioavailability< 10%
Protein binding76%
MetabolismFirst pass elimination > 90%
Elimination half-life2-4 hours (plasma)
Excretion> 88% renal (as carboxybupranolol)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H22ClNO2
Molar mass271.78298 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Bupranolol

Articles

Most recent articles on Bupranolol

Most cited articles on Bupranolol

Review articles on Bupranolol

Articles on Bupranolol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bupranolol

Images of Bupranolol

Photos of Bupranolol

Podcasts & MP3s on Bupranolol

Videos on Bupranolol

Evidence Based Medicine

Cochrane Collaboration on Bupranolol

Bandolier on Bupranolol

TRIP on Bupranolol

Clinical Trials

Ongoing Trials on Bupranolol at Clinical Trials.gov

Trial results on Bupranolol

Clinical Trials on Bupranolol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bupranolol

NICE Guidance on Bupranolol

NHS PRODIGY Guidance

FDA on Bupranolol

CDC on Bupranolol

Books

Books on Bupranolol

News

Bupranolol in the news

Be alerted to news on Bupranolol

News trends on Bupranolol

Commentary

Blogs on Bupranolol

Definitions

Definitions of Bupranolol

Patient Resources / Community

Patient resources on Bupranolol

Discussion groups on Bupranolol

Patient Handouts on Bupranolol

Directions to Hospitals Treating Bupranolol

Risk calculators and risk factors for Bupranolol

Healthcare Provider Resources

Symptoms of Bupranolol

Causes & Risk Factors for Bupranolol

Diagnostic studies for Bupranolol

Treatment of Bupranolol

Continuing Medical Education (CME)

CME Programs on Bupranolol

International

Bupranolol en Espanol

Bupranolol en Francais

Business

Bupranolol in the Marketplace

Patents on Bupranolol

Experimental / Informatics

List of terms related to Bupranolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and Dosage

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.

Pharmacology

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.

Adverse Effects, Contraindications, Interactions

Adverse effects, contraindications and interactions are similar to other beta blockers.

References


Linked-in.jpg